Columbus Macro LLC Has $2.32 Million Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Columbus Macro LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 55.9% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 25,103 shares of the biopharmaceutical company's stock after purchasing an additional 9,004 shares during the quarter. Columbus Macro LLC's holdings in Gilead Sciences were worth $2,319,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Trust Point Inc. boosted its stake in Gilead Sciences by 4.2% during the 4th quarter. Trust Point Inc. now owns 4,213 shares of the biopharmaceutical company's stock valued at $389,000 after acquiring an additional 169 shares during the last quarter. Optas LLC acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at about $240,000. Jennison Associates LLC bought a new position in shares of Gilead Sciences during the fourth quarter worth about $87,163,000. Resonant Capital Advisors LLC grew its stake in Gilead Sciences by 16.2% in the fourth quarter. Resonant Capital Advisors LLC now owns 17,482 shares of the biopharmaceutical company's stock worth $1,615,000 after purchasing an additional 2,441 shares in the last quarter. Finally, Catalina Capital Group LLC increased its holdings in Gilead Sciences by 25.6% in the fourth quarter. Catalina Capital Group LLC now owns 4,844 shares of the biopharmaceutical company's stock valued at $447,000 after buying an additional 987 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Price Performance

Gilead Sciences stock traded down $2.00 during trading hours on Friday, hitting $96.04. 7,182,199 shares of the company traded hands, compared to its average volume of 6,916,494. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $100.51. The firm has a market cap of $119.69 billion, a P/E ratio of 1,067.11, a P/E/G ratio of 1.37 and a beta of 0.18. The firm's 50-day simple moving average is $92.97 and its two-hundred day simple moving average is $86.49. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating analysts' consensus estimates of $1.58 by $0.44. The business had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business's revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter last year, the business earned $2.29 earnings per share. As a group, analysts forecast that Gilead Sciences, Inc. will post 4.34 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on GILD shares. Oppenheimer increased their target price on Gilead Sciences from $105.00 to $115.00 and gave the stock an "outperform" rating in a report on Tuesday, December 10th. Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a report on Thursday, November 7th. BMO Capital Markets increased their target price on shares of Gilead Sciences from $94.00 to $102.00 and gave the stock an "outperform" rating in a report on Thursday, November 7th. UBS Group lifted their price target on shares of Gilead Sciences from $70.00 to $96.00 and gave the company a "neutral" rating in a report on Thursday, November 21st. Finally, Citigroup began coverage on shares of Gilead Sciences in a research note on Thursday, November 14th. They set a "buy" rating and a $125.00 price objective on the stock. Eleven investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $98.39.

Insider Buying and Selling at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 142,180 shares of the stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the completion of the sale, the chief financial officer now directly owns 129,873 shares of the company's stock, valued at $12,626,253.06. This represents a 52.26 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jeffrey Bluestone sold 6,788 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the transaction, the director now owns 8,920 shares in the company, valued at approximately $815,198.80. This trade represents a 43.21 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 572,824 shares of company stock valued at $53,611,715. 0.29% of the stock is owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.